Business Context and Reporting Period
This Form 8-K is a current report filed by Zafgen, Inc. on March 6, 2018. The filing announces the company's financial results for the fourth quarter of 2017 and the full fiscal year ended December 31, 2017. The registrant is incorporated in Delaware and maintains its principal executive offices in Boston, Massachusetts. Note: The request metadata references "Larimar Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Zafgen, Inc.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this Form 8-K.
Material Changes
The filing does not describe specific material changes versus the prior comparable period within the text provided. It serves solely as a notification that the results for the fourth quarter and full year 2017 have been announced.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It includes a standard disclaimer stating that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release) referenced in this filing.
- Confirm the distinction between the metadata company name (Larimar Therapeutics) and the actual registrant (Zafgen, Inc.) to ensure the correct entity is being analyzed.
- Review the full press release for any operational updates, clinical trial milestones, or liquidity concerns not summarized in this 8-K.